復鋭醫療科技(01696.HK)擬配售最多2400萬股 總籌6.216億港元
格隆匯7月20日丨復鋭醫療科技(01696.HK)發佈公吿,2021年7月19日,公司與配售代理(即瑞銀、復星恆利及招銀國際)訂立配售協議,據此,配售代理各自按個別(而非共同或共同及個別)基準同意按盡力基準,作為公司的代理促使承配人認購最多2400萬股股份,配售價為每股25.90港元。
配售股份相當於該公吿日期公司已發行股本總額約5.43%及經配發及發行配售股份擴大後公司已發行股本總額約5.15%。每股配售股份配售價25.90港元較7月19日收市價29.70港元折讓約12.79%。
假設所有配售股份獲悉數配售,預期配售事項的所得款項總額合共約為6.216億港元,而預期配售事項的所得款項淨額合共約為6.1547億港元。擬用作開發及經營集團的注射填充業務(包括RT002(須待獨立股東批准公司與上海復星醫藥產業發展有限公司於2021年7月14日訂立的分許可協議及其項下擬進行的交易)或其他注射填充業務機會)以及醫學美容牙科及個人護理業務單元、擴大集團的全球銷售渠道及一般營運資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.